Phoenix Financial Ltd. Sells 36,970 Shares of Boston Scientific Corporation $BSX

Phoenix Financial Ltd. decreased its position in Boston Scientific Corporation (NYSE:BSX) by 32.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 76,308 shares of the medical equipment provider’s stock after selling 36,970 shares during the quarter. Phoenix Financial Ltd.’s holdings in Boston Scientific were worth $7,450,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Riverwater Partners LLC grew its stake in Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management grew its position in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC grew its position in Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the last quarter. IVC Wealth Advisors LLC increased its holdings in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its position in Boston Scientific by 3.9% in the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 103 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 1.2%

NYSE:BSX opened at $93.66 on Tuesday. The firm has a market capitalization of $138.85 billion, a price-to-earnings ratio of 50.09, a PEG ratio of 1.68 and a beta of 0.67. The business’s 50-day moving average price is $95.54 and its two-hundred day moving average price is $99.76. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 80,204 shares of company stock valued at $7,998,563 in the last quarter. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on BSX. The Goldman Sachs Group restated a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, January 9th. Oppenheimer decreased their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Needham & Company LLC reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. Finally, Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $123.89.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.